Xintela's interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically s ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Beginning with its exatecan ADC, STRO-004, aimed at Tissue Factor, the biotechnology company situated in South San Francisco ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner ...

In a recent study published in the Journal of Experimental Medicine, a multi-institutional research team led by Osaka ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...

Researchers from Osaka University found that plasma cells expressing high levels of the protein integrin β7 and the ...

Researchers from Osaka University have discovered that the protein subunit AP2A1 may play a role in the unique structural ...

9Department of Chemistry, University of Missouri, Columbia, Missouri. 10Department of Radiology, University of Missouri, Columbia, Missouri. Search for other works by this author on: 3Molecular ...